鎌状赤血球症治療の世界市場レポート 2024年

鎌状赤血球症治療の市場規模は近年急速に拡大しています。2023年の24億6,000万米ドルから2024年には29億5,000万米ドルに、CAGR20.0％で拡大します。実績期間の成長は、疾患理解、輸血、疼痛管理、ヒドロキシ尿素療法に起因します。

輸血のニーズの高まりは、当面の鎌状赤血球症治療市場の拡大を促進すると予想されます。輸血は、ドナーからレシピエントへの血液または血液製剤の移送を伴う医療処置です。輸血は、血液の酸素運搬能力を高め、血管閉塞に伴う合併症を軽減することで、鎌状赤血球症（SCD）患者の治療に重要な役割を果たしています。たとえば、2022年12月、gov.UKによると、英国では2021年に献血が増加し、全国で170万件の献血が行われました。さらに、2022年1月、Mid-Atlantic Long-Term Careによると、米国では1日に約29,000単位の赤血球、5,000単位の血小板、6,500単位の血漿が必要とされています。従って、輸血需要の増加が鎌状赤血球症治療市場成長の原動力となっています。

血液移植や骨髄移植の普及率が高まっていることが、鎌状赤血球症治療市場の成長を牽引すると予想されます。血液移植や骨髄移植は、不健康な造血細胞を健康な造血細胞に置き換える医療処置です。これらの移植は、病気の骨髄を治療して異常細胞を除去した後に、健康な骨髄細胞を個人に注入することによって、鎌状赤血球症や様々ながんを治療することを目的としています。移植される細胞は、患者自身の体から採取されるもの（自家移植）と、ドナーの体から採取されるもの（同種移植）があります。例えば、2023年6月、米国保健資源サービス庁は、2021年に米国では非血縁者間5,073件、血縁者間4,276件の骨髄・臍帯血移植が行われたと報告しました。さらに、登録された骨髄ドナーの数は、2021年の9,285,029人から9,475,534人に増加しました。このように、血液および骨髄移植の普及率の上昇は、鎌状赤血球症治療市場を大きく押し上げると予想されます。

2023年の鎌状赤血球症治療市場で最大の地域は北米でした。鎌状赤血球症治療レポートがカバーしている地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の鎌状赤血球症治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 輸血
• 薬物療法
• 骨髄移植
• 世界の鎌状赤血球症治療市場、疾患タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 鎌状赤血球貧血
• ヘモグロビン鎌状C病（HbSC）
• その他
• 世界の鎌状赤血球症治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• 世界の鎌状赤血球症治療市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック
• その他

第7章 地域および国の分析

• 世界の鎌状赤血球症治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の鎌状赤血球症治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 鎌状赤血球症治療市場の競合情勢
• 鎌状赤血球症治療市場の企業プロファイル
  • Sun Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Johnson &Johnson Private Limited
  • Merck &Co Inc.
  • Novartis AG

第31章 その他の主要および革新的な企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Silver Lake Research Corporation0.45
• Global Blood Therapeutics Inc.
• Acceleron Pharma Inc.
• Sangamo Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Sickle Cell Disease Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sickle cell disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sickle cell disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The sickle cell disease treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Treatment Modality: Blood Transfusion; Pharmacotherapy; Bone Marrow Transplant
• 2) By Disease Type: Sickle Cell Anemia; Hemoglobin Sickle C Disease (HbSC); Other Disease Types
• 3) By Route Of Administration: Oral; Parenteral
• 4) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Sickle cell disease (SCD), also referred to as sickle cell anemia, is a genetic disorder that impacts hemoglobin, a protein found in red blood cells. Individuals with sickle cell disease produce defective hemoglobin, known as hemoglobin S (HbS), due to a mutation in the hemoglobin gene. Treatment for sickle cell disease aims to alleviate blockages, improve blood flow, and repair damaged tissues.

The primary modalities for treating sickle cell disease include blood transfusion, pharmacotherapy, and bone marrow transplant. A blood transfusion involves the transfer of blood or blood products from a donor to a recipient. Sickle cell disease encompasses various types, such as sickle cell anemia, hemoglobin sickle C disease (HbSC), and others, with treatment administered through oral and parenteral routes. End users of these treatments include hospitals, specialty clinics, and other healthcare facilities.

The sickle cell disease treatment market research report is one of a series of new reports from The Business Research Company that provides sickle cell disease treatment market statistics, including sickle cell disease treatment industry global market size, regional shares, competitors with a sickle cell disease treatment market share, detailed sickle cell disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the sickle cell disease treatment industry. This sickle cell disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $2.46 billion in 2023 to $2.95 billion in 2024 at a compound annual growth rate (CAGR) of 20.0%. The growth in the historic period can be attributed to disease understanding, blood transfusions, pain management, hydroxyurea therapy.

The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $5.75 billion in 2028 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to gene editing and gene therapy, new drug development, telemedicine and remote monitoring, global health initiatives. Major trends in the forecast period include curative therapies, pain management alternatives, global collaborations, patient advocacy and engagement.

The growing need for blood transfusions is expected to propel the expansion of the sickle cell disease treatment market in the foreseeable future. Blood transfusion is a medical procedure involving the transfer of blood or blood products from a donor to a recipient. It plays a crucial role in the treatment of sickle cell disease (SCD) patients by enhancing the blood's oxygen-carrying capacity and reducing the complications associated with vaso-occlusion. For example, in December 2022, gov.UK reported that the UK witnessed an increase in blood donations in 2021, with 1.7 million donations made across the country. Moreover, in January 2022, according to Mid-Atlantic Long-Term Care, the United States requires approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma daily. Therefore, the growing demand for blood transfusions is a driving force behind the growth of the sickle cell disease treatment market.

The increasing prevalence of blood and bone marrow transplants is expected to drive the growth of the sickle cell disease treatment market. Blood and bone marrow transplants are medical procedures that involve the replacement of unhealthy blood-forming cells with healthy ones. These transplants aim to cure sickle cell diseases and various cancers by infusing healthy bone marrow cells into individuals after treating their diseased bone marrow to eliminate abnormal cells. The replacement cells can either be obtained from the patient's own body (autologous transplant) or from a donor's body (allogeneic transplant). For instance, in June 2023, the Health Resources and Services Administration reported that in 2021, the United States conducted 5,073 unrelated and 4,276 related bone marrow and cord blood transplants. Additionally, the number of registered bone marrow donors increased from 9,285,029 in 2021 to 9,475,534 in 2021. Thus, the rising prevalence of blood and bone marrow transplants is expected to significantly boost the sickle cell disease treatment market.

The significant medical costs are exerting a negative influence on the growth of the sickle cell disease treatment market during the forecast period. The elevated expenses associated with medical care for individuals with SCD can create substantial financial barriers. Patients and their families may encounter challenges in affording essential treatments, medications, and hospitalizations, leading to delays or inadequacies in care. For example, in July 2022, as reported by the National Library of Medicine, patients with SCD incurred greater costs, with an annual cost difference ranging from $6,636 to $43,436 compared to those without SCD. Inpatient care, with costs ranging from $11,978 to $59,851 per year, was the medical expense that significantly impacted SCD patients. Therefore, the high medical costs are impeding the growth of the sickle cell disease treatment market.

Prominent companies operating in the sickle cell disease treatment market are strategically pursuing new product approvals to advance their positions in the market. The approval of drugs for the treatment of sickle cell disease aims to provide more effective treatment options for patients dealing with this lifelong condition. For instance, in December 2021, Global Therapeutics Inc., a biopharmaceutical company based in the United States, announced the rapid approval granted by the U.S. FDA for Oxbryta (voxelotor) tablets. These tablets are intended for the treatment of sickle cell disease (SCD) in children aged between 4 and 11 years. Oxbryta is the sole FDA-approved medication for children with SCD, specifically targeting the prevention of sickle hemoglobin polymerization, which is the underlying cause of sickling and the destruction of red blood cells in SCD. This innovative drug, classified as first-in-class, works by increasing the production of fetal hemoglobin (HbF) through its interaction with and activation of the TNSALP enzyme. This activation allows the enzyme to break down pyrophosphate, a substance that can interfere with HbF production. Oxbryta is administered via a subcutaneous injection once daily.

In October 2022, Pfizer Inc., a pharmaceutical corporation headquartered in the United States, acquired Global Blood Therapeutics Inc. for $5.4 billion. This acquisition provides Pfizer with access to a premier sickle cell disease portfolio and pipeline, addressing the critical needs of an underserved patient population. Global Blood Therapeutics Inc. is a biopharmaceutical company based in the United States, specializing in the development and commercialization of therapies for individuals with sickle cell disease (SCD).

Major players in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

North America was the largest region in the sickle cell disease treatment market in 2023. The regions covered in sickle cell disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sickle cell disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sickle cell disease treatment market consists of revenues earned by entities by providing services such as oxygen therapy, pulmonary hypertension management and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The sickle cell disease treatment market also includes sales of hydroxyurea, L-glutamine and voxlelotor. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Sickle Cell Disease Treatment Market Characteristics

3. Sickle Cell Disease Treatment Market Trends And Strategies

4. Sickle Cell Disease Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Sickle Cell Disease Treatment Market Size and Growth

• 5.1. Global Sickle Cell Disease Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Sickle Cell Disease Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Sickle Cell Disease Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Sickle Cell Disease Treatment Market Segmentation

• 6.1. Global Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant
• 6.2. Global Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Sickle Cell Anemia
• Hemoglobin Sickle C Disease (HbSC)
• Other Disease Types
• 6.3. Global Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• 6.4. Global Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users

7. Sickle Cell Disease Treatment Market Regional And Country Analysis

• 7.1. Global Sickle Cell Disease Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Sickle Cell Disease Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Sickle Cell Disease Treatment Market

• 8.1. Asia-Pacific Sickle Cell Disease Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Sickle Cell Disease Treatment Market

• 9.1. China Sickle Cell Disease Treatment Market Overview
• 9.2. China Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Sickle Cell Disease Treatment Market

• 10.1. India Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Sickle Cell Disease Treatment Market

• 11.1. Japan Sickle Cell Disease Treatment Market Overview
• 11.2. Japan Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Sickle Cell Disease Treatment Market

• 12.1. Australia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Sickle Cell Disease Treatment Market

• 13.1. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Sickle Cell Disease Treatment Market

• 14.1. South Korea Sickle Cell Disease Treatment Market Overview
• 14.2. South Korea Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Sickle Cell Disease Treatment Market

• 15.1. Western Europe Sickle Cell Disease Treatment Market Overview
• 15.2. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Sickle Cell Disease Treatment Market

• 16.1. UK Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Sickle Cell Disease Treatment Market

• 17.1. Germany Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Sickle Cell Disease Treatment Market

• 18.1. France Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Sickle Cell Disease Treatment Market

• 19.1. Italy Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Sickle Cell Disease Treatment Market

• 20.1. Spain Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Sickle Cell Disease Treatment Market

• 21.1. Eastern Europe Sickle Cell Disease Treatment Market Overview
• 21.2. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Sickle Cell Disease Treatment Market

• 22.1. Russia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Sickle Cell Disease Treatment Market

• 23.1. North America Sickle Cell Disease Treatment Market Overview
• 23.2. North America Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Sickle Cell Disease Treatment Market

• 24.1. USA Sickle Cell Disease Treatment Market Overview
• 24.2. USA Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Sickle Cell Disease Treatment Market

• 25.1. Canada Sickle Cell Disease Treatment Market Overview
• 25.2. Canada Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Sickle Cell Disease Treatment Market

• 26.1. South America Sickle Cell Disease Treatment Market Overview
• 26.2. South America Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Sickle Cell Disease Treatment Market

• 27.1. Brazil Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Sickle Cell Disease Treatment Market

• 28.1. Middle East Sickle Cell Disease Treatment Market Overview
• 28.2. Middle East Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Sickle Cell Disease Treatment Market

• 29.1. Africa Sickle Cell Disease Treatment Market Overview
• 29.2. Africa Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Sickle Cell Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Sickle Cell Disease Treatment Market Competitive Landscape
• 30.2. Sickle Cell Disease Treatment Market Company Profiles
  • 30.2.1. Sun Pharmaceutical Industries Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Johnson & Johnson Private Limited
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Sickle Cell Disease Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Eli Lilly and Company
• 31.5. Gilead Sciences Inc.
• 31.6. Amgen Inc.
• 31.7. Baxter International Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Vertex Pharmaceuticals Incorporated
• 31.10. Alnylam Pharmaceuticals Inc.
• 31.11. Ionis Pharmaceuticals Inc.
• 31.12. Silver Lake Research Corporation0.45
• 31.13. Global Blood Therapeutics Inc.
• 31.14. Acceleron Pharma Inc.
• 31.15. Sangamo Therapeutics Inc.

32. Global Sickle Cell Disease Treatment Market Competitive Benchmarking

33. Global Sickle Cell Disease Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Sickle Cell Disease Treatment Market

35. Sickle Cell Disease Treatment Market Future Outlook and Potential Analysis

• 35.1 Sickle Cell Disease Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Sickle Cell Disease Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Sickle Cell Disease Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer